1. Home
  2. UFI vs RNTX Comparison

UFI vs RNTX Comparison

Compare UFI & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unifi Inc. New

UFI

Unifi Inc. New

HOLD

Current Price

$4.62

Market Cap

76.4M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.00

Market Cap

80.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UFI
RNTX
Founded
1969
2001
Country
United States
United States
Employees
N/A
10
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.4M
80.7M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
UFI
RNTX
Price
$4.62
$1.00
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
73.7K
591.2K
Earning Date
05-05-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$571,344,000.00
N/A
Revenue This Year
$1.39
N/A
Revenue Next Year
$12.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.96
$0.85
52 Week High
$5.30
$2.18

Technical Indicators

Market Signals
Indicator
UFI
RNTX
Relative Strength Index (RSI) 69.32 48.28
Support Level $4.29 $0.99
Resistance Level $4.74 $1.33
Average True Range (ATR) 0.21 0.09
MACD 0.04 0.01
Stochastic Oscillator 89.04 70.95

Price Performance

Historical Comparison
UFI
RNTX

About UFI Unifi Inc. New

Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: